The Albany Gazette - Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting

NYSE - LSE

RIO	2.84%	84.01	$
BP	-2.1%	46.61	$
RYCEF	2.04%	17.19	$
GSK	4.1%	50.78	$
NGG	2.03%	84.55	$
BTI	2.85%	62.685	$
CMSC	-0.15%	19.82	$
BCE	2.84%	21.14	$
BCC	2.72%	76.9	$
RELX	4.69%	41.34	$
RBGPF	0%	70.49	$
VOD	3.7%	16.22	$
AZN	2.38%	188.37	$
CMSD	0%	19.86	$
JRI	0.96%	11.47	$

Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting

BOULEVARD 04.11.2026

Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting

Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma

Text size:

CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12-15, 2026, in New Orleans, Louisiana. mRNA-2808 is an investigational multiplexed mRNA therapeutic designed to enable in vivo production of three distinct T-cell engagers targeting BCMA, GPRC5D and FcRH5.

At the time of the abstract submission, 12 heavily pretreated patients with relapsed or refractory multiple myeloma (median 10 prior lines of therapy) had received mRNA-2808 in the ongoing Phase 1/2 MyEngage trial (NCT07116616). Four confirmed responses, including two very good partial responses (VGPRs) and two partial responses (PRs), were observed among 11 response-evaluable patients, including patients previously treated with BCMA- and/or GPRC5D-directed therapies. All three encoded T-cell engagers were detectable in plasma, with exposure increasing across dose levels, demonstrating in vivo protein production in humans. No dose-limiting toxicities or treatment-related serious adverse events were observed. Cytokine release syndrome occurred in 5 patients (41.7%), all Grade 1, without step-up dosing. Grade ≥3 treatment-related adverse events occurred in 41.7% of patients, predominantly hematologic.

The Company expects to present updated clinical data from the ongoing Phase 1/2 MyEngage trial at the ASH annual meeting in December.

Presentation Details

Abstract title: Initial results from a first-in-human phase 1/2 trial of mRNA-2808, a multiplexed mRNA therapeutic encoding BCMA, GPRC5D, and FcRH5-targeted T-cell engagers, in relapsed/refractory multiple myeloma
Presentation: Oral presentation, December 12, 2026, 2:15-2:30 PM CT, Abstract #266
Meeting: 68th ASH Annual Meeting, December 12-15, 2026, New Orleans, Louisiana

About mRNA-2808

mRNA-2808 is an investigational lipid nanoparticle-formulated multiplexed mRNA therapeutic being evaluated in an ongoing Phase 1/2 clinical study (NCT07116616) in patients with relapsed or refractory multiple myeloma.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the safety and efficacy of mRNA-2808; the potential of mRNA-2808 to treat relapsed or refractory multiple myeloma; the potential of Moderna's multiplexed mRNA approach to enable in vivo production of multiple distinct T-cell engagers; and the ongoing clinical development of mRNA-2808. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

(F.Allen--TAG)

Featured

Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months

Amazon UK sales up 90%: $2.27 million in TTM sales for the twelve months to November 2, 2026, up from approximately $1.19 million in the prior twelve months23% net margin on Amazon UK: the Amazon UK channel generated $525,000 in net profit after all direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT116,978 units sold on Amazon UK: an average of approximately 320 units per dayRecord performance: July through October 2026 were the four strongest months to date on Amazon UK, each with sales above $215,000Efficient growth: advertising costs of only 2.4% of Amazon UK sales, with refunds below 1%72% growth expected: the Company expects Amazon UK sales of approximately $3.9 million over the next twelve months, an average of approximately $325,000 per month

Medical Care Technologies Inc. (OTCID:MDCE) Moves $250,000 Software Agreement Into Active Development

Development Underway on Integrated Web Front-End and Custom Enterprise Backend Covering Inventory, Sales, and Ongoing Technical Support

Julia Stiles and Ezra Sosa Share Emotional Farewell After 'DWTS' Elimination

Julia Stiles and her Dancing With the Stars partner, Ezra Sosa, shared tearful interviews after being eliminated during "Disney Night." The pair reflected on their time together, with Sosa praising Stiles' influence on his personal growth and Stiles citing newfound confidence from the competition.

John Schneider Admits Owes Millions in 'Dukes of Hazzard' Divorce Battle

'Dukes of Hazzard' actor John Schneider has formally acknowledged a debt of roughly $3.7 million in back spousal support to his ex-wife, Elvira Schneider, marking a shift in their ongoing divorce proceedings. While admitting the financial obligation, Schneider is contesting a court order that would divert half of his Social Security benefits to satisfy the arrears.